| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 135K | 7.6M | 131.83M | 51.13M | 53.48M |
| Revenue Growth % | - | - | - | 55.3% | 16.35% | -0.61% | 0.05% |
| Cost of Goods Sold | 407K | 968K | 38.77M | 87.85M | 116.72M | 13.24M | 13.38M |
| COGS % of Revenue | - | - | 287.22% | 11.56% | 0.89% | 0.26% | 0.25% |
| Gross Profit | -407K | -968K | -38.64M | -80.25M | 15.11M | 37.89M | 40.1M |
| Gross Margin % | - | - | -286.22% | -10.56% | 0.11% | 0.74% | 0.75% |
| Gross Profit Growth % | - | -1.38% | -38.92% | -1.08% | 1.19% | 1.51% | 0.06% |
| Operating Expenses | 12.82M | 24.84M | 15.66M | 28.41M | 34.9M | 154.12M | 133.62M |
| OpEx % of Revenue | - | - | 116.01% | 3.74% | 0.26% | 3.01% | 2.5% |
| Selling, General & Admin | 2.91M | 4.95M | 15.66M | 28.41M | 34.9M | 33.76M | 32.22M |
| SG&A % of Revenue | - | - | 116.01% | 3.74% | 0.26% | 0.66% | 0.6% |
| Research & Development | 9.91M | 19.89M | 41M | 91.17M | 120.5M | 133.59M | 116.87M |
| R&D % of Revenue | - | - | 303.7% | 12% | 0.91% | 2.61% | 2.19% |
| Other Operating Expenses | -1.14M | 0 | -41M | -91.17M | -120.5M | -13.24M | -15.47M |
| Operating Income | -12.82M | -25.81M | -54.3M | -108.66M | -19.8M | -116.22M | -93.52M |
| Operating Margin % | - | - | -402.24% | -14.3% | -0.15% | -2.27% | -1.75% |
| Operating Income Growth % | - | -1.01% | -1.1% | -1% | 0.82% | -4.87% | 0.2% |
| EBITDA | -12.41M | -24.84M | -53.41M | -107.19M | -17.82M | -114.27M | -91.6M |
| EBITDA Margin % | - | - | -395.59% | -14.1% | -0.14% | -2.23% | -1.71% |
| EBITDA Growth % | - | -1% | -1.15% | -1.01% | 0.83% | -5.41% | 0.2% |
| D&A (Non-Cash Add-back) | 407K | 968K | 897K | 1.47M | 1.98M | 1.95M | 1.92M |
| EBIT | -13.92M | -26.45M | -54.3M | -108.66M | -19.8M | -116.22M | -92.14M |
| Net Interest Income | 0 | 0 | 240K | 259K | 5.63M | 13.33M | 10.39M |
| Interest Income | 0 | 0 | 240K | 259K | 5.63M | 13.33M | 10.39M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -1.43M | -644K | -440K | 74K | 5.9M | 13.04M | 10.27M |
| Pretax Income | -14.25M | -26.45M | -54.74M | -108.59M | -13.9M | -103.18M | -83.25M |
| Pretax Margin % | - | - | -405.5% | -14.29% | -0.11% | -2.02% | -1.56% |
| Income Tax | 35K | 761K | -1.32M | -1.68M | 15.15M | -9.38M | 1.44M |
| Effective Tax Rate % | 1% | 1.03% | 0.98% | 0.98% | 2.09% | 0.91% | 1.02% |
| Net Income | -14.28M | -27.22M | -53.42M | -106.91M | -29.05M | -93.8M | -84.69M |
| Net Margin % | - | - | -395.68% | -14.07% | -0.22% | -1.83% | -1.58% |
| Net Income Growth % | - | -0.91% | -0.96% | -1% | 0.73% | -2.23% | 0.1% |
| Net Income (Continuing) | -14.28M | -27.22M | -53.42M | -106.91M | -29.05M | -93.8M | -84.69M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.90 | -0.74 | -1.45 | -2.83 | -0.69 | -2.23 | -2.00 |
| EPS Growth % | - | 0.18% | -0.96% | -0.95% | 0.76% | -2.23% | 0.1% |
| EPS (Basic) | -0.90 | -0.74 | -1.45 | -2.83 | -0.69 | -2.23 | -2.00 |
| Diluted Shares Outstanding | 15.79M | 36.67M | 36.9M | 37.82M | 41.92M | 42.09M | 42.41M |
| Basic Shares Outstanding | 15.79M | 36.67M | 36.9M | 37.82M | 41.92M | 42.09M | 42.41M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 12.05M | 98.57M | 346.55M | 351.41M | 353.98M | 243.69M | 171.15M |
| Cash & Short-Term Investments | 10.73M | 94.8M | 333.71M | 341.87M | 343.94M | 223.63M | 152.79M |
| Cash Only | 10.73M | 94.8M | 326.18M | 334.43M | 159.52M | 111.27M | 84.72M |
| Short-Term Investments | 0 | 0 | 7.53M | 7.44M | 184.42M | 112.36M | 68.07M |
| Accounts Receivable | 1.06M | 3.06M | 6.16M | 3.23M | 4.32M | 15.31M | 12.35M |
| Days Sales Outstanding | - | - | 16.67K | 155.32 | 11.97 | 109.3 | 84.27 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 719K | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 1.88M | 4.12M | 10.53M | 17.3M | 10.1M | 10.21M | 5.36M |
| Property, Plant & Equipment | 1.65M | 3.42M | 8.62M | 13.1M | 9.6M | 7.54M | 4.22M |
| Fixed Asset Turnover | - | - | 0.02x | 0.58x | 13.73x | 6.78x | 12.68x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 198K | 208K | 212K | 0 | 0 | 2.28M | 0 |
| Other Non-Current Assets | 27K | 359K | 288K | 586K | 497K | 396K | 1.14M |
| Total Assets | 13.93M | 102.69M | 357.09M | 368.71M | 364.07M | 253.9M | 176.51M |
| Asset Turnover | - | - | 0.00x | 0.02x | 0.36x | 0.20x | 0.30x |
| Asset Growth % | - | 6.37% | 2.48% | 0.03% | -0.01% | -0.3% | -0.3% |
| Total Current Liabilities | 1.91M | 4.25M | 11.01M | 35.09M | 78.62M | 39.08M | 25.29M |
| Accounts Payable | 1.25M | 2.13M | 2.25M | 2.3M | 461K | 2.4M | 3.62M |
| Days Payables Outstanding | 1.12K | 802.02 | 21.19 | 9.56 | 1.44 | 66.17 | 98.85 |
| Short-Term Debt | 0 | 625K | 697K | 1.72M | 0 | 2.4M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 0 |
| Other Current Liabilities | 249K | 233K | 3.2M | 13.76M | 16.03M | 17.08M | 166K |
| Current Ratio | 6.32x | 23.22x | 31.46x | 10.01x | 4.50x | 6.24x | 6.77x |
| Quick Ratio | 6.32x | 23.22x | 31.46x | 10.01x | 4.50x | 6.24x | 6.77x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 34.4M | 8.58M | 59.24M | 45.2M | 5.94M | 2.74M | 88K |
| Long-Term Debt | 2.49M | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 439K | 3.31M | 5.59M | 3.26M | 1.01M | 88K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | -2.68M | 0 | 0 |
| Other Non-Current Liabilities | 31.91M | 0 | 0 | 0 | 2.68M | 0 | 0 |
| Total Liabilities | 36.31M | 12.83M | 70.26M | 80.29M | 84.56M | 41.82M | 25.38M |
| Total Debt | 2.49M | 1.06M | 4M | 7.31M | 5.43M | 3.41M | 1.93M |
| Net Debt | -8.24M | -93.73M | -322.18M | -327.11M | -154.09M | -107.86M | -82.78M |
| Debt / Equity | - | 0.01x | 0.01x | 0.03x | 0.02x | 0.02x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - |
| Total Equity | -22.38M | 89.87M | 286.83M | 288.42M | 279.52M | 212.08M | 151.13M |
| Equity Growth % | - | 5.01% | 2.19% | 0.01% | -0.03% | -0.24% | -0.29% |
| Book Value per Share | -1.42 | 2.45 | 7.77 | 7.63 | 6.67 | 5.04 | 3.56 |
| Total Shareholders' Equity | -22.38M | 89.87M | 286.83M | 288.42M | 279.52M | 212.08M | 151.13M |
| Common Stock | 1K | 1K | 384.31M | 480.7M | 482.03M | 483.35M | 486.67M |
| Retained Earnings | -22.73M | -49.94M | -103.36M | -210.27M | -239.31M | -333.11M | -417.8M |
| Treasury Stock | -340K | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -490K | 0 | 0 | 0 | -428K | 28K | 54K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.62M | -18.43M | -6.08M | -85.8M | 322K | -127.16M | -76.44M |
| Operating CF Margin % | - | - | -45.07% | -11.29% | 0% | -2.49% | -1.43% |
| Operating CF Growth % | - | -0.46% | 0.67% | -13.1% | 1% | -395.9% | 0.4% |
| Net Income | -14.28M | -27.22M | -53.42M | -106.91M | -29.05M | -93.8M | -84.69M |
| Depreciation & Amortization | 407K | 605K | 897K | 1.47M | 1.98M | 1.95M | 1.92M |
| Stock-Based Compensation | 306K | 511K | 2.54M | 12.83M | 19.69M | 25.06M | 23.17M |
| Deferred Taxes | 306K | 0 | 588K | 149K | 3.62M | 0 | 0 |
| Other Non-Cash Items | 1.13M | 1.08M | 890K | 1.87M | -3.94M | -5.19M | -2.79M |
| Working Capital Changes | -484K | 6.59M | 42.42M | 4.79M | 8.03M | -55.18M | -14.06M |
| Change in Receivables | -485K | -1.91M | -2.95M | 3M | -1.52M | -216K | 2.72M |
| Change in Inventory | 0 | 0 | 2.95M | -3M | 0 | 0 | 0 |
| Change in Payables | 10K | 833K | 17K | 152K | -1.35M | 1.93M | 1.23M |
| Cash from Investing | -583K | -1.3M | -9.76M | -1.68M | -175.78M | 78.04M | 49.47M |
| Capital Expenditures | -583K | -1.3M | -2.24M | -1.69M | -602K | -1.94M | 0 |
| CapEx % of Revenue | - | - | 16.57% | 0.22% | 0% | 0.04% | - |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -175.18M | 0 | 0 |
| Cash from Financing | 0 | 103.24M | 247.84M | 95.56M | 880K | 842K | 542K |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 15.8M | 1.27M | 0 | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -13.2M | -19.73M | -8.32M | -87.49M | -280K | -129.1M | -76.44M |
| FCF Margin % | - | - | -61.64% | -11.51% | -0% | -2.52% | -1.43% |
| FCF Growth % | - | -0.49% | 0.58% | -9.51% | 1% | -460.06% | 0.41% |
| FCF per Share | -0.84 | -0.54 | -0.23 | -2.31 | -0.01 | -3.07 | -1.80 |
| FCF Conversion (FCF/Net Income) | 0.88x | 0.68x | 0.11x | 0.80x | -0.01x | 1.36x | 0.90x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 23K | 156K | 25K | 10.81M | 4.95M | 139K |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -80.66% | -28.36% | -37.17% | -10.23% | -38.16% | -46.63% |
| Return on Invested Capital (ROIC) | - | - | - | - | -34.24% | -75.91% | -81.29% |
| Gross Margin | - | - | -28622.22% | -1055.97% | 11.46% | 74.11% | 74.98% |
| Net Margin | - | - | -39568.15% | -1406.68% | -22.03% | -183.44% | -158.37% |
| Debt / Equity | - | 0.01x | 0.01x | 0.03x | 0.02x | 0.02x | 0.01x |
| FCF Conversion | 0.88x | 0.68x | 0.11x | 0.80x | -0.01x | 1.36x | 0.90x |
| Revenue Growth | - | - | - | 5529.63% | 1634.61% | -61.21% | 4.58% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| SWITZERLAND | - | 116.6M | 14.5M | 50.89M |
| SWITZERLAND Growth | - | - | -87.56% | 250.95% |
| UNITED STATES | - | 15.2M | 26.1M | 2.59M |
| UNITED STATES Growth | - | - | 71.71% | -90.08% |
| JAPAN | - | - | 10.5M | - |
| JAPAN Growth | - | - | - | - |
| U S | 7.6M | - | - | - |
| U S Growth | - | - | - | - |
Repare Therapeutics Inc. (RPTX) reported $11.9M in revenue for fiscal year 2024.
Repare Therapeutics Inc. (RPTX) grew revenue by 4.6% over the past year. Growth has been modest.
Repare Therapeutics Inc. (RPTX) reported a net loss of $72.2M for fiscal year 2024.
Repare Therapeutics Inc. (RPTX) has a return on equity (ROE) of -46.6%. Negative ROE indicates the company is unprofitable.
Repare Therapeutics Inc. (RPTX) had negative free cash flow of $70.1M in fiscal year 2024, likely due to heavy capital investments.